Last $0.30 USD
Change Today 0.00 / 0.00%
Volume 0.0
LIXT On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

lixte biotechnology holdings (LIXT) Key Developments

Lixte Biotechnology Holdings, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 04:50 PM

Lixte Biotechnology Holdings, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 04:50 PM. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland.

Lixte Biotechnology Holdings, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 03:45 PM

Lixte Biotechnology Holdings, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 03:45 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States.

Lixte Biotechnology Holdings, Inc. Auditor Raises 'Going Concern' Doubt

Lixte Biotechnology Holdings, Inc. filed its 10-K on Mar 21, 2014 for the period ending Dec 31, 2013. In this report its auditor, Weinberg & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Daniel Von Hoff Joins Lixte Biotechnology's Scientific Advisory Board

Lixte Biotechnology Holdings, Inc. announced the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board. Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen.

Lixte Biotechnology Holdings, Inc. Announces Initiation of a Materials Cooperative Research and Development Agreement With National Institute of Neurological Disorders and Stroke, National Institutes of Health

Lixte Biotechnology Holdings, Inc. has signed a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS, NIH). Under this agreement, the Surgical Neurology Branch of NINDS, NIH, will conduct research characterizing a variety of compounds proprietary to Lixte. This research will examine the compounds' potential for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases. Under an M-CRADA, a party provides research material, in this case proprietary compounds from Lixte's pipeline, for study by scientists at NIH. The exchange of materials is for research only and implies no endorsement of the materials on the part of either party.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LIXT:US $0.30 USD 0.00

LIXT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LIXT.
View Industry Companies
 

Industry Analysis

LIXT

Industry Average

Valuation LIXT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 23.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIXTE BIOTECHNOLOGY HOLDINGS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.